Lantern Pharma Inc (LTRN)
6.13
-0.01
(-0.16%)
USD |
NASDAQ |
May 17, 16:00
6.00
-0.13
(-2.12%)
After-Hours: 20:00
Lantern Pharma Research and Development Expense (Annual): 11.89M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 11.89M |
| December 31, 2022 | 8.603M |
| December 31, 2021 | 7.571M |
| Date | Value |
|---|---|
| December 31, 2020 | 2.243M |
| December 31, 2019 | 0.9532M |
| December 31, 2018 | 0.5721M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
0.9532M
Minimum
2019
11.89M
Maximum
2023
6.253M
Average
7.571M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Eyenovia Inc | 12.98M |
| Cassava Sciences Inc | 89.42M |
| Alpine Immune Sciences Inc | 80.90M |
| Clearside Biomedical Inc | 20.85M |
| Poseida Therapeutics Inc | 156.77M |